Companies / Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc.

Nasdaq: ZVRACIK 1434647BOSTON, MA

Financials · FY2015

Revenue$0
Net income$83.23M
Total debt$0
Cash$145.32M
Diluted EPS$1.35
Shares outstanding59.4M

Ownership

59.4M shares outstanding · as of Jul 31, 2026
1.1%Insiders
Ownership
Insiders1.11%662,135
Institutions65.62%38,967,838
Public float33.26%19,753,808

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 9

View all →
Insider% of sharesShares
McFarlane Neil F.CEOPresident and CEO · Director
0.65%387,225
0.24%143,515
Bode John BDirector
0.21%123,400
0.10%62,278
Thompson RahsaanChief Legal & Compliance
0.08%49,919
Sangiovanni Timothy J.SVP, Finance & Corp Controller
0.05%29,590
Quartel Adrian WChief Medical Officer
0.02%9,723

Institutional holders 164

View all →

Activity

InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Feb 2, 2026McFarlane Neil F.
CEO
SellCommon Stock$853.4K-91K
-19.98%
364,350
0.61% of shares
medium
Dec 31, 2025Clifton R. LaDuaneOtherCommon Stock$434.7K-49K
-25.26%
143,515
0.24% of shares
low
Mar 24, 2026Bode John B
Director
ExerciseCommon Stock$194.8K+39K
+87.11%
84,200
0.14% of shares
low
Mar 24, 2026Bode John B
Director
ExerciseCommon Stock$191.7K+39K
+46.56%
123,400
0.21% of shares
low
Feb 9, 2026McFarlane Neil F.
CEO
SellCommon Stock$125.2K-15K
-3.64%
387,225
0.65% of shares
medium
Feb 3, 2026Schafer Joshua
Executive
SellCommon Stock$96.5K-11K
-14.43%
62,278
0.10% of shares
low
Jan 30, 2026Quartel Adrian W
Executive
SellCommon Stock$40.0K-5K
-31.80%
9,723
0.02% of shares
low
Jan 30, 2026Thompson Rahsaan
Executive
SellCommon Stock$36.0K-4K
-7.56%
49,919
0.08% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Vanguard Group IncPassive13G/A0

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
ZVRA488445206